Constimulus Bio, an enterprise in Zhongshan's National Health Technology Park, signed a cooperation agreement with Abogen Biosciences on December 6. The two sides will collaborate on the application research and development of agonistic antibodies and mRNA tumor therapeutic vaccines.

Constimulus Bio, which settled in the NHTP in 2021, focuses on the innovative transformation of the heavy chain constant region of agonistic antibody and is dedicated to the research and development of innovative drugs for agonistic antibodies. Abogen Biosciences is an innovative bio-pharmaceutical company specializing in mRNA drug development and is one of the earliest domestic pharmaceutical companies to do so.

This achievement follows another success from the previous week when Zhongshan Health Base Group and Wan Hongsheng Group signed a project agreement.

The factory Wan Hongsheng Group has leased in the NHTP covers an area of over 20,000 square meters and is used for the research and production of intelligent full-automatic nursing beds, electric scooters for the elderly, manual electric wheelchairs and etc. Its estimated annual output value can exceed 1 billion yuan after production.

Established in Shenzhen in 2007, Wan Hongsheng Group is mainly specialized in developing and producing medical, health-care and high-end smart household products. It plans to relocate its Shenzhen headquarters and subsidiaries to Zhongshan and go public in the future.

The NHTP was founded in 1994 and is now home to more than 400 enterprises in the massive health sector.